| Status: Medicine does not meet criteria for AWMSG assessment | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over |
|
Medicine details |
|
| Medicine name | baricitinib (Olumiant®) |
| Formulation | 2 mg, 4 mg film-coated tablet |
| Reference number | 5094 |
| Indication | for treating juvenile idiopathic arthritis in people 2 years and over |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 13/06/2024 |
| NICE guidance | TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over |